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Abstract
Pancreatic cancer is the deadliest of the gastrointestinal tract with 5-year survival rates 
of less than 5%. Given common asymptomatic early disease course, most patients (50%) 
present with an already metastatic disease, while only 20% can undergo potentially 
curative resection. The remaining 30% present with locally advanced disease, defined 
as extended vascular encasement, where the risk of surgical therapy often outweighs its 
benefits. Traditional thermal local ablative modalities (RFA, MWA, or cryotherapy) have 
the disadvantage that they are not applicable in proximity to vital vascular structures, 
which are abundant in the peripancreatic region. Irreversible electroporation (IRE) is an 
emerging non-thermal alternative that induces apoptosis of tumor cells by the delivery 
of short repetitive impulses of high-voltage electric current. Given its mostly non-ther-
mal modality, IRE is not hampered by a heat-sink effect and is applicable with little risk 
around vascular structures, bile and pancreatic ducts. Recent research suggests that local 
tumor destruction through IRE improves overall survival, progression-free survival and 
quality of life in patients with locally advanced pancreatic cancer.
Keywords: locally advanced pancreatic cancer, borderline resectable pancreatic cancer, 
irreversible electroporation, local tumor destruction, apoptosis, overall survival
1. Introduction
Pancreatic adenocarcinoma is a prevalent disease with 53,760 newly diagnosed patients in 
the United States in 2017 [1]. Despite the rapidly growing medical progress in the twenty-first 
century and extensive efforts in cancer research, pancreatic adenocarcinoma remains a highly 
aggressive malignancy with 5-year survival rate still not exceeding 5% [1, 2]. By extrapolating 
annual incidence rates, pancreatic adenocarcinoma is estimated to rise to the second leading 
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cause of cancer-related death in the United States by 2020 [3]. Unfortunately, only a minor-
ity of patients presented early during the disease course, and screening programs have been 
crowned by little success so far [4]. It is globally accepted that early detection of the tumor 
provides the only chance for cure, given that treatment modalities other than surgical resec-
tion are inherently palliative. Several clinical staging systems for patients with pancreatic 
adenocarcinoma exist, while all of them comply with the only potentially curative treatment 
option, that is, surgical resection. Thanks to more elaborate imaging techniques now widely 
available (high-resolution CT, MRI, endoscopic ultrasound), the tumor-vessel relationships 
can be determined with high precision rendering pretreatment staging increasingly accurate. 
Among others, one of the largely used and accepted staging definitions has been established 
by the National Comprehensive Cancer Network (NCCN) [5]. This classification groups pan-
creatic adenocarcinoma into four categories such as resectable, borderline resectable, locally 
advanced and metastatic disease [6].
Definition according to the National Comprehensive Cancer Network (NCCN) [6]:
Resectable tumor: no distant metastases, no radiographic evidence of superior mesenteric vein 
(SMV) and/or portal vein (PV) abutment, distortion, tumor thrombus, or venous encasement. 
Clear fat planes around the celiac axis, hepatic artery and superior mesenteric artery (SMA).
Borderline resectable: no distant metastases, encasement of the SMV/PV but without encase-
ment of the nearby arteries or short segment venous occlusion resulting from either tumor 
thrombus or encasement but with suitable vessel proximal and distal to the area of vessel 
involvement, allowing for safe resection and reconstruction. Gastroduodenal artery encase-
ment up to the hepatic artery, without extension to the celiac axis. Tumor abutment of the 
SMA not to exceed >180° of the circumference of the vessel wall (Figure 1).
Locally advanced (unresectable): tumor involvement or occlusion of the SMV or PV, which pre-
cludes reconstruction of vessels or greater than 180° tumor contact with either SMA, celiac 
artery or any involvement of first jejunal branch of SMA or Aorta (Figure 2).
Figure 1. Borderline resectable pancreatic cancer. Tumor with contact to the SMV (black arrow).
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Metastatic disease: presence of distant metastases (e.g. hepatic, peritoneal, or other) (Figure 3).
At the time of diagnosis, only approximately 20% of patients present with a resectable or bor-
derline resectable disease. If treated by surgical resection with negative histological margins 
(R0) followed by adjuvant chemotherapy, this patient group can achieve a 5-year survival 
rate of about 20% [2, 5]. While 50% of patients initially present with metastatic disease, the 
remnant 30% show a locally advanced stage with involvement of vital adjacent structures as 
defined earlier. While the diagnosis of resectable and metastatic disease usually is simple, the 
distinction between borderline resectable and locally advanced disease can be challenging. 
In patients with borderline resectable disease, the involvement of major vessels is less exten-
sive, and a macroscopic negative resection margin (e.g., with segmental/partial resection of 
venous structures) is potentially achievable without adding major morbidity [7]. In contrast, 
patients with locally advanced pancreatic cancer are often characterized by arterial vessel 
involvement. A resection with negative margins in these cases is technically rarely feasible 
Figure 2. Locally advanced pancreatic cancer. Encasement of the superior mesenteric artery (black arrow).
Figure 3. Metastatic pancreatic cancer. Liver metastasis (black arrow).
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and often implies arterial resection associated with high perioperative morbidity and mortal-
ity [8–11]. A timely meta-analysis by Mollberg et al. assessed the impact of arterial resection 
on perioperative outcomes among patients undergoing pancreatic resection. They showed that 
perioperative morbidity and mortality was, with 53 and 12%, significantly higher for patients 
with arterial resection compared to around 25–30 and 6% reported for pancreatoduodenecto-
mies, not requiring arterial reconstruction, respectively [12–14]. In summary, given the high 
perioperative risk and its limited impact on survival, arterial resection can at present not be 
justified as a standard procedure in the treatment of pancreatic cancer [2, 10]. Accordingly, 
the current treatment recommendations for patients with locally advanced pancreatic cancer 
are chemo- and/or radiotherapy, which achieve a median overall survival of 9–13 months on 
average [2]. There is notably a difference in the standard treatment regimens according to the 
geographic location; most patients in the USA with locally advanced pancreatic cancer are cur-
rently undergoing combined chemoradiotherapy, whereas patients in the Europe are usually 
treated with chemotherapy alone. Recent advances in chemotherapy allow to downstage cer-
tain patients with locally advanced disease, making a surgical resection of some tumors possible 
[15, 16]. Patients treated with neoadjuvant chemotherapy followed by surgical resection can 
achieve similar survival rates like patients diagnosed in a resectable or borderline resectable 
state. It is estimated that in select patient cohorts, up to one-third of patients initially judged as 
non-resectable can be converted into a resectable state by neoadjuvant chemotherapy. However, 
the neoadjuvant regimen is still debated and is not internationally accepted yet as standard of 
care [17, 18].
Given that patients with locally advanced disease have a poor prognosis despite multimodal 
therapy, additional treatment alternatives are desperately needed. In the group of locally 
advanced pancreatic cancer, the tumor is confined to the location of origin without evidence 
of distant spread—rendering local therapy an attractive additional treatment option. As such, 
loco-regional therapies including radiofrequency ablation (RFA), microwave ablation (MWA) 
and irreversible electroporation (IRE) have gained increased attention in the treatment of locally 
advanced pancreatic adenocarcinoma over the last years [19, 20].
2. Local ablative strategies
2.1. Thermal local ablative strategies
Radiofrequency (RFA) and microwave ablation (MWA) have been used in an attempt to achieve 
local control among patients with locally advanced pancreatic cancer. Both treatments generate 
thermal energy by a high-frequency alternating current, which is delivered to the cancerous 
tissue by one or more needle electrodes. The created high local temperature at the tip of the 
electrodes leads to cell death by coagulative necrosis and protein denaturation [21, 22]. RFA has 
been used with success in the setting of unresectable tumors in multiple solid organs (liver, lung, 
kidney, brain, breast, prostate, bone, adrenal glands, spleen) [22]. Over the last years, it has also 
been deployed in the palliative setting of locally advanced pancreatic cancer. However, RFA in 
patients with pancreatic adenocarcinoma has not been widely accepted because of considerable 
morbidity and mortality rates [19]. The high complication rate was thought to be due to thermal 
injury to the multiple delicate structures (bile duct, pancreatic duct, duodenum, vital vessels) 
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surrounding the pancreas. By adjusting the administered temperature from 105 to 90°C for 
5 min’ length, complications in recent patient cohorts treated by RFA were substantially reduced 
[20]. Still, gastrointestinal hemorrhages, acute pancreatitis, pancreatic/biliary fistulas, duode-
nal injury and portal vein thrombosis are regularly reported in the literature [19]. A systematic 
review from 2014 cited an RFA-related morbidity ranging from 10 to 37% and an RFA-related 
mortality from 0 to 19% [23]. Another important downside of thermal ablative therapies is the 
so-called “heat-sink effect.” During the ablation process, adjacent blood vessels are “cooling the 
tissue down” leading to an insufficient temperature in the immediate proximity of the vessels, 
where therefore efficient cell death cannot be induced [24]. Given the anatomical complexity of 
the pancreatic region and bearing the abovementioned aspects in mind, it is self-evident that 
the application of thermal ablative therapy in locally advanced pancreatic cancer is delicate. It 
is at this state unknown whether RFA should be combined with chemo- and/or radiotherapy 
as a standard treatment. A retrospective analysis of patients with locally advanced pancreatic 
cancer with short induction chemotherapy and RFA compared to a patient group with RFA 
did not show a difference in early disease progression or overall survival [25]. While there is no 
evidence from randomized controlled trials regarding the oncological outcome of RFA in locally 
advanced disease, several case series show a significantly increased median overall survival in 
patients where RFA was part of the treatment concept [26, 27].
MWA is less prone to the heat-sink effect compared to RFA and is therefore more suitable for 
application closer to large vessels. Similar to RFA, no randomized data using MWA in locally 
advanced pancreatic cancer are available [28]. Given the heterogeneous reports of MWA and 
RFA, direct comparisons between the two techniques in regard of long-term survival are cur-
rently not available. However, based on published evidence, MWA seems to lead to less post-
operative pain and decreased ablation time with similar results in morbidity and mortality 
compared to RFA [29]. However, at present, MWA is still studied less extensively than RFA 
[30, 31].
2.2. Irreversible electroporation
2.2.1. Introduction to IRE
Irreversible electroporation (IRE) is an emerging ablative modality that gained enormous 
interest over the last years. In contrast to the abovementioned thermal ablative strategies, 
IRE leads to cell death mainly through a nonthermal technique. In IRE, high voltage (maxi-
mum of 3000 V) electrical pulses of 70–90 μs duration are applied through a minimum of 
two electrodes positioned next to or into the target neoplastic tissue. The thus created elec-
trical field leads to a disruption of the cell membrane’s lipophilic bilayer by formation of 
nanoscale micropores. This damage to the cell membrane eventually leads to a collapse of 
intracellular homeostasis and an activation of apoptotic pathways, finally resulting in cell 
death. The distinct advantage of this technique compared to thermal ablative strategies is the 
preservation of structural components like collagen and elastin as thermal damage does only 
occur in the very close proximity to the ablation needles depending on pulse length, exposure 
of the needle tips, delivered energy, distance between the electrodes and underlying tissue. 
Another advantage of IRE compared to thermal ablative modalities is its nonexisting “heat 
sink effect,” which means that the efficiency of IRE will not be reduced in proximity to large 
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vessels [21, 32]. For the above-cited reasons, IRE is a very attractive local ablation method in 
pancreatic cancer, given the inherent proximity of the pancreas to vital vascular structures as 
well as the bile and pancreatic duct.
However, IRE cannot be applied under any circumstances given that several contraindications 
for its use exist. The presence of metallic material in close proximity to the placed IRE needles 
(e.g., metallic biliary stent that is not removable) is a relative contraindication for IRE, given that 
the conductivity of the metal could potentiate the minimal thermal effect of it. Even more impor-
tantly, the presence of metal can distract, respectively, and derivate the electrical current used in 
IRE, rendering prediction of the ablation zone impossible. Hence the effect of IRE is potentially 
dangerous [33, 34]. Also, a tumor size >5 cm is generally seen as a contraindication, given that the 
volume of the ablation zone of a tumor exceeding this size is technically difficult to achieve [21]. 
Additionally, IRE is contraindicated in patients with certain cardiac arrhythmias, and patients 
with pacemakers should be evaluated by a cardiologist prior to IRE, as the high-voltage electric 
current applied can itself provocate potentially serious arrhythmias [32]. To avoid such complica-
tions in ablations at the level of the pancreas, the electrical pulses are applied during the complete 
refractory phase of the heart (50 ms after the R wave). To achieve the coordination of the IRE 
pulses and the heart rhythm of the patient, the IRE device is synchronized with the patient’s 
ECG. Furthermore, application of IRE is not recommended in patients having a history of epi-
lepsy or recent myocardial infarction. No data exist about the use of IRE in pregnancy.
2.2.2. IRE in locally advanced pancreatic cancer
IRE has first been established as a complementary local therapy in conjunction with chemo-
therapy for patients with locally advanced pancreatic cancer, which is not amenable to surgical 
resection [30]. In situations where surgical resection seems too risky (e.g., a tumor encapsulating 
the superior mesenteric artery), IRE has shown to be a safe and valuable treatment alternative. 
Standalone IRE without surgical resection of the primary tumor is called “in situ” IRE. Its pri-
mary aim is to achieve maximal local tumor control. As in thermal ablative strategies, there is cur-
rently no randomized data available that look at oncological outcomes of (radio-) chemotherapy 
and IRE compared to (radio-) chemotherapy alone. However, there is encouraging evidence that 
suggests a relevant improvement of overall survival in patients with in situ IRE after induction 
chemotherapy/(radio-) chemotherapy [2, 35]. A propensity-matched score analysis by Martin 
et al. showed a survival benefit of induction chemotherapy and/or radiation followed by IRE 
compared to (radio-) chemotherapy alone. The additional treatment with IRE showed a prolon-
gation of local progression free survival from 6 to 14 months, distant progression free survival 
from 9 to 15 months and overall survival from 13 to 20 months [35]. Another study analyzing 
200 patients with locally advanced pancreatic cancer, either undergoing in situ IRE or margin 
accentuation IRE after an induction chemotherapy/(radio-)chemotherapy showed an encourag-
ing median overall survival of 24.9 months and local recurrence rates of only 3% [36]. These 
results indicate that local tumor control with IRE is achievable and has a significant positive 
effect on patients with locally advanced pancreatic cancer. However, the interpretation of data 
on long-term oncological outcomes after IRE is still difficult, given that the studies available are 
of substantial heterogeneity and mostly lacking direct control groups. Additionally, most stud-
ies were not primarily designed to demonstrate oncological efficacy of the procedure but rather 
aimed to demonstrate safety and efficacy of the IRE procedure itself [2]. Some authors emphasize 
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the possible impact of neoadjuvant chemotherapy over the direct effect of IRE given that the spe-
cific impact of IRE has not yet been demonstrated. However, Gillen et al. found a median overall 
survival of 22 months in patients with locally advanced pancreatic cancer treated with neoadju-
vant chemotherapy and if possible subsequent pancreatic resection [17]. These survival outcomes 
are still slightly worse than the ones of the 200 patients documented by Martin et al. in his cohort 
undergoing in situ IRE/margin accentuation IRE with pancreatic resection. IRE thus seems to add 
some additional benefit that systemic chemotherapy cannot provide, most probably by its local 
field of action. This observation has led to the hypothesis that the resection margin in pancreatic 
cancer deserves further investigation, as IRE might contribute to better overall survival by achiev-
ing more “true” R0 resections (see Chapter 4) [37]. Additional studies focusing on overall survival 
are certainly needed to further investigate the potential of IRE in improving the outcomes of 
patients with locally advanced pancreatic cancer.
2.3. Induction therapy in locally advanced pancreatic cancer before in situ IRE
At present, in situ IRE is mainly recommended in combination with upfront chemotherapy 
or (radio-) chemotherapy for at least 3 months. This does not only allow a “test for time” to 
get familiar with the biology of the patients underlying tumor, but also avoids local treatment 
with in situ IRE among patients with metastatic disease. Several induction treatment regimens 
have been suggested while so far no specific data are available, which favor one regimen over 
the other. Gemcitabine-based chemotherapy and/or radiotherapy is an option; however, more 
recent studies show beneficial results with the more aggressive FOLFIRINOX regimen as initial 
therapy [38–40]. Given the significant toxicity of FOLFIRINOX, a modified regimen has been 
suggested, where the 5-FU bolus is left out [15]. An alternative chemotherapy regimen often 
used in advanced pancreatic cancer and also in the setting of induction therapy before IRE 
is the combination of gemcitabine and Nab-paclitaxel [41]. Further studies assessing the best 
inductive treatment before IRE are needed before any general recommendation can be given.
Whatever induction therapy is used, it must be followed by restaging investigations. While 
there is no standard algorithm recommended, we perform a 3-phase contrast enhanced pan-
creas protocol computer tomography including the chest, to exclude pulmonary metastases 
and to plan the IRE procedure in detail. High quality CT-scans allow for sound judgment of 
tumor vessel relationships. In addition, given that diffusion MRI of the liver has shown to 
outperform CT-scans in regard of detection of liver metastases, all patients will undergo this 
imaging tool prior to surgical exploration [42].
3. Technique of IRE
3.1. General considerations
As mentioned earlier, all eligible patients for in situ IRE with locally advanced pancreatic 
cancer have to complete at least 3 months of neoadjuvant (radio-) chemotherapy, mainly to 
avoid local IRE treatment in patients with metastatic disease. This said, restaging after fin-
ishing induction treatment is crucial and should be performed with major diligence. Note-
worthy is the usually absent “radiographic response” in pancreatic imaging after neoadjuvant 
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Figure 4. (a and b) Parallel placement of two needles at the distance of 2 cm for an IRE treatment around the common 
hepatic artery.
therapy—consensus is therefore to proceed to in situ IRE unless imaging shows local disease 
progression or newly observed distant metastases [2, 35, 36].
In case restaging confirms the presence of locally advanced pancreatic adenocarcinoma, every 
patient should be discussed at an interdisciplinary tumor board including medical oncologists, 
radiation oncologists, radiologists, pathologists and surgical oncologists. If tumor response is 
achieved and the lesion can be downstaged to borderline resectable disease, patients should 
be considered for surgical resection with margin-accentuation IRE (see part 4). In cases of 
stable disease without development of distant metastases and a maximal tumor diameter of 
<5 cm, patients can be planned for in situ IRE.
3.2. Practice of IRE
3.2.1. Open approach
Technically, there are different ways to apply IRE to a target lesion. Practice in our institution is 
at the moment the “classical” open abdominal approach. An upper midline or transverse inci-
sion is performed followed by a meticulous abdominal exploration looking for occult metastatic 
disease. IRE needles are then placed under ultrasound guidance covering the suspected tumor 
area. At least two unipolar probes are needed to deliver the high-voltage current. Parallel orien-
tation of the needles is of utmost importance, with ideally a distance of about 2 cm between each 
needle pair (Figures 4 and 5).
A maximum of six probes can be inserted at the same time [43]. During the IRE procedure 
itself, full neuromuscular relaxation has to be guaranteed as the high voltages transmitted by 
the electrodes can produce significant muscular contractions [44]. If successful ablation was per-
formed at one site, needle pull-back can be repeated as many times as needed with performance 
of the treatment at another level in order to cover the full desired ablation volume. Early imaging 
documentation of the success of IRE treatment is not possible, given the unspecific postoperative 
changes. As such, control imaging by CT-scan is not recommended before 3 months after IRE, as 
the images can be altered by ongoing edema following electroporation [45].
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3.2.2. Minimal-invasive approach
IRE may also be applied in the setting of minimally invasive surgery under laparoscopic ultra-
sound guidance [46].
Additionally, surgical interventions like hepaticojejunostomy or gastroenterostomy, which 
have the potential to improve the quality of life in patients suffering from locally advanced 
pancreatic adenocarcinoma, can be performed during the same intervention in patients 
receiving IRE by either an open or a laparoscopic approach.
3.2.3. Percutaneous approach
Several groups have gained experience in the percutaneous application of IRE supported 
by different imaging modalities. Narayanan et al. reported a series of 50 patients with 
CT-guided percutaneous IRE. The procedure was technically feasible in all patients. A 
median overall survival of 27 months from the time of diagnosis and 14 months from the 
time of IRE was reported, which is comparable to the oncological outcomes observed in 
open IRE [47]. Another group around Mansson performed IRE under ultrasound guid-
ance. Of the 24 patients, all treatments were completed using ultrasound guidance only 
[48]. The case series presented are small, but the data suggest that the percutaneous 
approach is technically feasible and generally safe [47, 48]. A potential drawback of the 
percutaneous approach is the lack of visual assessment of the peritoneal cavity. Small 
liver/peritoneal lesions can be missed and patients with potential metastatic disease might 
be “locally overtreated,” given that at present no data for application of IRE in metastatic 
settings exist.
Figure 5. Intraoperative needle positioning under ultrasound guidance. In this example the two needle tips (red arrows) 
are placed to the left and right of the superior mesenteric artery (*).
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3.3. Potential complications of IRE
Despite its nonthermal technique, also IRE is associated with potential complications. In the 
so far largest population from Martin et al. consisting of 200 patients treated with IRE, a 
total rate of 37% adverse events were recorded along with a mortality rate of 2%. The most 
common adverse events reported were pancreatic leak, pancreatitis and duodenal ulcer for-
mation. Also, less frequently vascular complications (such as hepatic arterial thrombosis or 
mesenteric/portal vein thrombosis) and liver dysfunction/failure have been observed [36]. A 
group from Scandinavia analyzed the so-far gained IRE experience in a recent review includ-
ing 10 studies comprising 446 patients in total (304 patients treated with open IRE and 142 
patients treated percutaneously). A total of nine fatalities (2%) were recorded, while overall 
complication rate was summarized to be 35% [37]. It has to be kept in mind that complications 
after open IRE are challenging to interpret, as in many cases, patients had major gastrointesti-
nal surgery in addition to their IRE treatment. However, whereas most complications seemed 
self-limited, there have been several reports on severe complications in open IRE such as 
portal vein thrombosis, pancreatic fistula and pancreatitis. Overall complications following 
percutaneous IRE vary from 0 to 20% in the different study groups. In the abovementioned 
population of 50 patients from Narayanan et al., most patients described postinterventional 
abdominal pain, 10 patients (20%) were reported to have a severe complication, but no IRE-
related deaths occurred [47].
4. Navigated IRE
An additional, novel technology is the so-called navigated IRE. One of the most critical and 
difficult steps of IRE is the correct positioning of the needles in accurate depth and perfect 
parallelism. If IRE is performed in an open fashion, the placement of the needles is normally 
controlled under ultrasound guidance. However, given the complex anatomical situation 
around the pancreas, 3D reconstructions based on preoperative imaging can provide the sur-
geon with a better topologic understanding of the patient’s specific anatomy. Those recon-
structions can nowadays be transferred to planning tools and even be used intraoperatively 
as navigational help. It has been shown that the ability to plan procedures on these image data 
and visualize them during the surgery holds significant value as different surgical strategies 
can be evaluated on the 3D models preoperatively and can be used as additional patient-
specific information throughout the surgery (Figure 6) [49, 50].
In 2005, Grenacher et al. discussed the role of computer-assisted surgery (CAS) in the field of 
liver and pancreas surgery [51]. Up to then, CAS was well established in surgical procedures 
related to orthopedics and neurosurgery, but the advantage of transferring the knowledge 
to soft tissue applications was insufficiently studied. However, advances in computer sci-
ence nowadays enable intraoperative navigation in hepato-pancreato-biliary surgery. Using 
the CAScination® system, the real world can be linked to tThe virtual scene, either by using 
landmarks on the surface of the organs or by using ultrasound to mark internal structures like 
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tumors or bifurcations of vessels [52]. The surgical instruments are then equipped with mark-
ers, which can be detected by an optical tracking system in real time (Figure 7).
A specific solution for IRE treatment of the pancreas has been implemented, which provides 
the surgeon with the possibility to preoperatively verify the needle placement based on given 
constraints like parallelism and spacing between the needles [53]. The aim of this novel tech-
nique in IRE would be the placement of the needles under live CAS-guidance according to the 
preoperatively defined plan. Nevertheless, further improvements of the intraoperative navigation 
Figure 6. 3D reconstruction showing the arteries (red), veins (blue), tumor of the pancreatic body (yellow), duodenum 
(green) and the pancreas (light green).
Figure 7. Demonstration of equipment for navigated IRE: touch screen (red arrow); infra red detection device (black 
arrow); metal spheres required for real-time instrument tracking consisting of instrument and ultrasound (white arrow).
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tools are required before they can be implemented to clinical routine and will be tackled by our 
team in the near future (Figure 8).
5. Additional indications: margin accentuation IRE
In recent years, the indications of IRE have been expanded to the so-called “margin accentu-
ation” IRE, typically in patients with borderline resectable pancreatic cancer. In this patient 
group, IRE is used as an adjunct to surgery intraoperatively, aiming to achieve a higher 
percentage of negative margin resections [32]. It is well known that margin-negative resec-
tion is a strong indicator for better overall survival in pancreatic cancer. However, isolated 
local recurrences are observed in 35–80% of patients after intended R0 resection, raising 
the hypothesis that R1 resections are underestimated [54, 55]. A comprehensive work-up 
done by Esposito et al. confirmed that almost 80% of the patients had a true R1 resection, if 
a thorough examination is performed by the pathologist [56]. It is commonly accepted that 
R1 resections are associated with worse outcome as compared to R0 resections. In addition, 
there are different R0 definitions used in the current literature: no microscopic tumor at 
the or within 1 mm of the resection margin [57]. Hence, the role of R1 resections is not yet 
entirely clear—some advocate that R1 margins have a negative impact on the overall sur-
vival, whereas others state that R1 margins do influence local recurrence rates, without hav-
ing a significant effect on survival [58–61]. Margin-accentuation IRE has been implemented 
in multiple pancreatic centers aiming to achieve a higher “true” R0 percentage and to there-
fore potentially increase overall survival and decrease local recurrences. At the present time, 
there are no clear recommendations of when margin accentuation IRE should be performed, 
because there are no clear radiological signs of when a microscopic positive resection mar-
gin has to be expected. Given the true R1-resection rate of up to 80%, one might argue that 
every patient with suspected or proven pancreatic cancer should have a margin accentua-
tion IRE, if the additional procedure risk is limited and operation time is not significantly 
prolonged. However, as long as no data are published on the benefit of margin accentua-
tion IRE over surgical resection only, the indication remains somewhat arbitrary. Further 
Figure 8. Preoperative 3D planning of an in situ IRE with 4 needles in a patient with locally advanced pancreatic cancer.
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research is definitely needed to assess the independent effect of margin accentuation IRE on 
local recurrence rates and overall survival.
6. Conclusions
Pancreatic cancer remains a highly lethal disease. Especially patients with locally advanced 
pancreatic cancer usually face a discouraging prognosis with limited treatment options. The 
local ablative therapy with IRE is a valuable additional treatment modality, which, looking at 
present evidence, seems to have the potential to improve disease-specific and overall survival 
among patients with this dreadful disease. IRE is technically feasible and generally safe in 
its open and minimal-invasive access. It can either be applied as in situ IRE in unresectable 
cases or as a complementary treatment to surgery in borderline resectable patients in order to 
improve the percentage of true R0 resections. Despite being now an accepted and increasingly 
applied therapy, there are still a lot of open questions regarding the use of IRE. Future efforts 
should aim toward the establishment of standard treatment protocols for IRE, in order to make 
its potential benefit available to more patients suffering from pancreatic adenocarcinoma.
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